Podcasts and video interviews with researchers, commentators, and experts in the field

Pulling Back the Curtain: Richard W. Childs, MD

Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...

LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease

Interim data from a phase I study of LentiGlobin BB305 in patients with severe sickle cell disease (SCD) suggest that the gene therapy was...

Pulling Back the Curtain: Angela Thomas, OBE, PhD

Hear more from our interview with Dr. Thomas, where she talks about "converting" trainees to pediatric hematology and offers career advice for early-career hematologists.

Pulling Back the Curtain: Allison Rosenthal, DO

Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she's ever received and the best (and worst) parts of...

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...

Does Blinatumomab Affect CAR T-Cell Therapy Response?

In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...

Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment

Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory...

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.

Current Issue

November 2018, Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.